These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 11948464)

  • 21. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.
    Rongcun Y; Salazar-Onfray F; Charo J; Malmberg KJ; Evrin K; Maes H; Kono K; Hising C; Petersson M; Larsson O; Lan L; Appella E; Sette A; Celis E; Kiessling R
    J Immunol; 1999 Jul; 163(2):1037-44. PubMed ID: 10395702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD3+CD56+CD8+ cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients.
    Akagi J; Takai E; Tamori Y; Ogawa M
    Int J Oncol; 2001 Sep; 19(3):561-6. PubMed ID: 11494036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
    Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
    BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of melanoma-specific peptide epitopes by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Ge HL; Wang Y; Wang SJ; Zhang Y
    Acta Biochim Biophys Sin (Shanghai); 2006 Feb; 38(2):110-8. PubMed ID: 16474902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
    Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ
    Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
    Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
    J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells.
    Peiper M; Goedegebuure PS; Eberlein TJ
    Surgery; 1997 Aug; 122(2):235-41; discussion 241-2. PubMed ID: 9288128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes.
    Kono K; Sato E; Naganuma H; Takahashi A; Mimura K; Nukui H; Fujii H
    Clin Cancer Res; 2004 Apr; 10(7):2538-44. PubMed ID: 15073134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
    Efferson CL; Schickli J; Ko BK; Kawano K; Mouzi S; Palese P; García-Sastre A; Ioannides CG
    J Virol; 2003 Jul; 77(13):7411-24. PubMed ID: 12805440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
    Zaks TZ; Rosenberg SA
    Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression.
    Kono K; Halapi E; Hising C; Petersson M; Gerdin E; Vanky F; Kiessling R
    Int J Cancer; 1997 Jan; 70(1):112-9. PubMed ID: 8985099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells.
    Anderson LD; Hudson JM; Savary CA; Fisk B; Gershenson DM; Ioannides CG
    Cancer Immunol Immunother; 1999 Oct; 48(7):401-10. PubMed ID: 10501854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
    Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro.
    Fisk B; Chesak B; Pollack MS; Wharton JT; Ioannides CG
    Cell Immunol; 1994 Sep; 157(2):415-27. PubMed ID: 7915203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
    Romagnani C; Pietra G; Falco M; Mazzarino P; Moretta L; Mingari MC
    Hum Immunol; 2004 May; 65(5):437-45. PubMed ID: 15172443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.
    Okugawa T; Ikuta Y; Takahashi Y; Obata H; Tanida K; Watanabe M; Imai S; Furugen R; Nagata Y; Toyoda N; Shiku H
    Eur J Immunol; 2000 Nov; 30(11):3338-46. PubMed ID: 11093150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
    Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
    Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
    Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.